Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 3/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALPG | P10696 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | AGPAT2 | O15120 | 5/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.33 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3577903 | 0.77 | NOTUM (0.49) | SCN9AEGFRERBB3CNR1CNR2 | |
| SCHEMBL4897073 | 0.72 | GRIN2D (0.38) | MAPTMEN1RAB9AKMT2AKDM4E | |
| SCHEMBL4015010 | 0.71 | CCNT1 (0.46) | SCN9AEGFRERBB3CNR1CNR2 | |
| SCHEMBL3577056 | 0.70 | CNR1 (0.45) | SCN9AEGFRERBB3CNR1CNR2 | |
| SCHEMBL4899608 | 0.69 | CYP1A2 (0.41) | EGFRMAPTMEN1RAB9AKMT2A | |
| SCHEMBL3578621 | 0.68 | CNR1 (0.48) | SCN9AEGFRERBB3CNR1CNR2 | |
| SCHEMBL182108 | 0.68 | MEN1 (0.47) | MAPTMEN1RAB9AKMT2AKDM4E | |
| SCHEMBL29620951 | 0.67 | EGLN1 (0.47) | CNR2KMT2AALDH1A1NPC1CYP1A2 | |
| SCHEMBL22925971 | 0.67 | EGLN1 (0.47) | CNR2KMT2AALDH1A1NPC1CYP1A2 | |
| SCHEMBL4899881 | 0.67 | TSHR (0.39) | MAPTMEN1RAB9AKMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100035934-A1 | PYRIDINYL-PYRAZOLE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S | 2010-02-11 | — | — | US | claimed |
| EP-2114916-A2 | PYRIDINYL-PYRAZOLE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NeuroSearch A/S (DK) | 2009-11-11 | — | — | EP | claimed |
| WO-2008092942-A2 | PYRIDINYL-PYRAZOLE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2008-08-07 | — | — | WO | claimed |
| US-20100035934-A1 | PYRIDINYL-PYRAZOLE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S | 2010-02-11 | — | — | US | disclosed |
| EP-2114916-A2 | PYRIDINYL-PYRAZOLE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NeuroSearch A/S (DK) | 2009-11-11 | — | — | EP | disclosed |
| WO-2008092942-A2 | PYRIDINYL-PYRAZOLE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2008-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035934-A1 | PYRIDINYL-PYRAZOLE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | KCNJ2, KCNA3, KCNQ1 | SCN9A 135/4885EGFR 4540/4885ERBB3 3819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.